Seltorexant


Selective orexin-2 receptor antagonist (2-SORA) with antidepressant and sleep-promoting activity

A selective orexin-2 receptor antagonist developed by Janssen Pharmaceuticals and Minerva Neurosciences as an adjunctive treatment for major depressive disorder with insomnia symptoms, distinguished from dual orexin receptor antagonists by its high OX2R selectivity, rapid pharmacokinetic profile, and demonstrated antidepressant efficacy through modulation of orexinergic hyperarousal.

Abstract

Seltorexant (JNJ-42847922, MIN-202) is a selective, high-affinity antagonist of the orexin-2 receptor (OX2R) and the first selective 2-SORA to advance through Phase 3 clinical trials for major depressive disorder (MDD) with insomnia symptoms. The compound exhibits approximately 100-fold selectivity for OX2R over OX1R and negligible affinity for other receptors, transporters, or ion channels in a panel of 50 assays, a selectivity profile that distinguishes it mechanistically from the dual orexin receptor antagonists (DORAs) suvorexant, lemborexant, and daridorexant approved for primary insomnia. Pharmacokinetics are characterized by rapid oral absorption (median time to maximum plasma concentration 0.3 to 1.5 hours), a short elimination half-life of approximately 2 to 3 hours, and metabolism predominantly through cytochrome P450 3A4, producing a pharmacokinetic profile suited to bedtime administration with minimal next-day residual effects. Preclinical pharmacology in rodent models demonstrated dose-dependent increases in non-rapid eye movement (NREM) sleep duration, reduced sleep onset latency, attenuation of stress-induced adrenocorticotropic hormone (ACTH) release, suppression of hypothalamic-pituitary-adrenal (HPA) axis activation, and absence of effects on dopaminergic reward pathways or motor coordination. The specificity of these effects for OX2R was confirmed by the absence of activity in OX2R knockout mice. Brain penetration and receptor occupancy were confirmed by positron emission tomography imaging in rats and by in vivo competitive radioligand binding studies. The clinical evidence base spans Phase 1 through Phase 3 development. The pivotal Phase 3 MDD3001 trial achieved its primary and all secondary endpoints, with seltorexant 20 mg adjunctive to SSRI or SNRI producing a statistically significant least-squares mean difference from placebo of negative 2.6 points on MADRS total score at day 43 (p = 0.007) and significant improvement in PROMIS Sleep Disturbance (negative 3.7, p < 0.001). The Phase 3 MDD3005 active-comparator study against quetiapine extended-release demonstrated a numerically higher response rate for seltorexant (57.4 percent versus 53.4 percent) that did not reach statistical significance, but with substantially fewer adverse events, lower somnolence incidence (6 percent versus 24 percent), and markedly less weight gain (0.5 kg versus 2.1 kg over 26 weeks). A separate monotherapy Phase 1b study (2024) in 128 MDD patients demonstrated antidepressant activity independent of adjunctive SSRI or SNRI use. The compound is well tolerated across the clinical program. The most common treatment-emergent adverse events are headache, somnolence, and nausea at incidences comparable to placebo. No deaths, serious treatment-emergent adverse events, clinically significant cardiovascular changes, or suicidal behavior events have been reported in the seltorexant treatment arms. No cataplexy has been observed. The compound does not produce conditioned place preference in mice, does not increase extracellular dopamine release in rat nucleus accumbens, and does not impair motor coordination at sleep-promoting doses, supporting a favorable abuse liability and safety profile relative to benzodiazepines and Z-drugs. Seltorexant has not yet received regulatory approval in any jurisdiction. Phase 3 clinical trials for adjunctive MDD with insomnia symptoms are ongoing, and Phase 2 investigation for primary insomnia and Alzheimer's disease is in progress. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph